An update from Celcuity ( (CELC) ) is now available.

A cohort study of people who underwent fecal immunochemical (FIT) screening for colorectal cancer showed that interval cancer ...

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast ...

Celcuity recently released positive results from its phase 3 VIKTORIA-1 trial, and is raising both debt and shares. Read what ...

The algorithm, developed by AI specialist Lunit, was retrospectively tested in conjunction with an advanced 3D mammography ...

Celcuity Inc. (Nasdaq: CELC) (the “Company”), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the pricing of its underwritten public ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity InsiderNews Commentary – The average age of cancer patients is getting younger, as experts are ...

Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Celcuity ( (CELC) ) just unveiled an ...

Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, B.C., July 29, 2025 /PRNewswire/ -- Equity Insider News Commentary - The average age of cancer patients is getting younger, ...

We recently published These 10 Stocks are Winning Big. Celcuity Inc. (NASDAQ:CELC) is one of the best-performing stocks on ...

Celcuity stock (NASDAQ: CELC), a clinical-stage biotechnology company, experienced an extraordinary 3x surge in a single ...

At a stroke, the data gives Celcuity a potential advantage over already-marketed oral PI3K inhibitors like Novartis' ...